Central Nervous System Tumors

A central nervous system (CNS) tumor begins when healthy cells in the brain or the spinal cord change and grow out of control, forming a mass, or tumor. If the tumor is malignant, it can spread to other parts of the body or brain, effecting a child’s thought processes and movements.

Our neuro-oncology team leads many different CNS tumor trials in coordination with sites around the world testing combinations of existing treatments, new approaches to radiation therapy or surgery, and new ways to relieve symptoms and side effects during treatment.

Phase 1 Study of Modified Measles Virus (MV-NIS) for the treatment of Children and Young Adults with Recurrent Medulloblastoma or Recurrent Atypical Teratiod Rhadoid Tumors (ATRT)

Protocol ID: PNOC005

Disease: CNS

Who can participate?: Patients must be > 365 days and < 10 years of age (for B-ALL patients); Patients must be >365 days and ≤ 30.99 years of age (for B-LLy patients).

Lead Researcher: Mark A. Ranalli, MD

Late Effects After High Risk Neuroblastoma Study

Protocol ID: ALTE15N2

Disease: NBL

Who can participate?: 1 to ≤ 18 years

Lead Researcher: Mark A. Ranalli, MD

Phase 2 Study of Reduced Therapy for Newly Diagnosed Average Risk WNT-Driven Medulloblastoma Patients

Protocol ID: ACNS1422

Disease: CNS

Who can participate?: Patients < 30 are eligible for enrollment.

Lead Researcher: Mark A. Ranalli, MD

Phase 2 Trial of Response Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)

Protocol ID: ACNS1123

Disease: CNS

Who can participate?: Participants 0 through 21 years of age are eligible; irrespective of eligibility for other COG studies.

Lead Researcher: Mark A. Ranalli, MD

Newly Diagnosed Children (Less Than 10 Years Old) with Medulloblastoma and Other Central Nervous System Primitive Neuro-ectodermal Tumors: Clinical and Molecular Risk-Tailored Intensive Compressed Induction Chemotherapy Followed by Consolidation with either Single Cycle (Low Risk Patients) To either Single-Cycle or To Three Tandem Cycles of Marrow-Ablative Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue

Protocol ID: Head Start 4

Disease: CNS

Who can participate?: Children less than 10 years of age at the time of definitive confirmatory eligible histologic or cytological diagnosis of eligible CNS tumor within the brain or spinal cord, who have not previously received either irradiation or chemotherapy (except corticosteroids) will be eligible for study entry.

Lead Researcher: Jonathan L. Finlay, MB, ChB, FRCP

A Phase III Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults with Previously Untreated Low Grade Glioma

Protocol ID: LGG-1403 Untreated LGG

Disease: CNS

Who can participate?: Patients must be less than 21 years of age at study entry.

Lead Researcher: Diana S. Osorio, MD

A Phase II Study of 131I-Metaiodobenzylguanidine (131I - MIBG) Therapy for Patients with MIBG Avid Tumors

Protocol ID: MIBG

Disease: NBL

Who can participate?: Patients must be between 12 months and 65 years at the time of study enrollment.

Lead Researcher: Mark A. Ranalli, MD

NMTT - Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)

Protocol ID: NMTRC014

Disease: NBL

Who can participate?: ≤ 30.99 years of age and classified as high risk by the criteria used by COG or SIOPEN at the time of diagnosis.

Lead Researcher: Keri A. Streby, MD

Epigenetic Molecular Profiling of Brain Tumors

Protocol ID: NYU-S14-00948

Disease: CNS

Who can participate?: All ages

Lead Researcher: Diana S. Osorio, MD

Phase II Study of Everolimus for Recurrent or Progressive Low-Grade Gliomas in Children (CC# 120817)

Protocol ID: PNOC-001

Disease: CNS

Who can participate?: Age ≥3 and ≤21 years

Lead Researcher: Mohamed S. AbdelBaki, MD

Safety, Phase 0, and Pilot Efficacy Study of vemurafenib, an oral inhibitor of BRAFV600E, in Children and Young Adults with Recurrent/Refractory BRAFV600E- or BRAF Ins T mutant Brain Tumors

Protocol ID: PNOC-002

Disease: CNS

Who can participate?: Patients ≤ 25 years of age will be eligible for the expansion cohort

Lead Researcher: Mohamed S. AbdelBaki, MD

Pilot Study of a Surgery and Chemotherapy-Only Approach in the Upfront Therapy of Children with WNT Positive Standard Risk Medulloblastoma

Protocol ID: J1403

Disease: Medulloblastoma

Who can participate?: Children at least 3 years of age and less than or equal to 18 years of age at diagnosis

Lead Researcher: Mohamed S. AbdelBaki, MD